KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal Shah, Roch Houot, Armin Ghobadi et al.|The Lancet|2021Cited by 795
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R. Bishop, Jason R. Westin, Michael Dickinson et al.|New England Journal of Medicine|2021Cited by 532
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal Shah, William G. Wierda, Michael R. Bishop et al.|Blood|2021Cited by 204
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal Shah, Roch Houot, Armin Ghobadi et al.|Journal of Hematology & Oncology|2022Cited by 78
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisNico Gagelmann, Nicolaus Kröger, Michael R. Bishop et al.|Transplantation and Cellular Therapy|2024Cited by 45